stockrowHims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) Shares outstanding
Hims & Hers Health, Inc.'s shares outstanding at the end of fiscal 2025 was $258.2M, up 9.05% from $236.8M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $231.7M. Over the past ten years it has ranged from $34.8M (fiscal 2019) to $258.2M (fiscal 2025) — the current reading is the highest in ten years. Hims & Hers Health, Inc. ranks 15th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $258.2M | 9.05% |
| FY2024 | $236.8M | 13.12% |
| FY2023 | $209.3M | 2.36% |
| FY2022 | $204.5M | 9.49% |
| FY2021 | $186.8M | 428.32% |
| FY2020 | $35.4M | 1.71% |
| FY2019 | $34.8M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $231.7M | 1.48% |
| Mar 2026 | $228.4M | (11.57%) |
| Dec 2025 | $258.2M | 3.84% |
| Sep 2025 | $248.7M | (3.16%) |
| 25 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RDY Dr. Reddy's Laboratories Ltd compare | $833.3M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $335.7M |
| HIMS Hims & Hers Health, Inc. | $231.7M |
| ALKS Alkermes plc compare | $176.4M |
| SUPN Indivior Pharmaceuticals Inc. compare | $122.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $111.2M |
| LQDA Liquidia Corporation compare | $101.4M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $84.9M |
| LNTH Lantheus Holdings, Inc. compare | $68.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on HIMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement